178 related articles for article (PubMed ID: 28410228)
1. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.
Li Q; Li B; Hu L; Ning H; Jiang M; Wang D; Liu T; Zhang B; Chen H
Oncotarget; 2017 May; 8(21):34687-34697. PubMed ID: 28410228
[TBL] [Abstract][Full Text] [Related]
2. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
3. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
[TBL] [Abstract][Full Text] [Related]
4. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
5. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
[TBL] [Abstract][Full Text] [Related]
7. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
8. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.
Hornakova T; Chiaretti S; Lemaire MM; Foà R; Ben Abdelali R; Asnafi V; Tartaglia M; Renauld JC; Knoops L
Blood; 2010 Apr; 115(16):3287-95. PubMed ID: 20167706
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
10. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
11. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.
Gordon GM; Lambert QT; Daniel KG; Reuther GW
Biochem J; 2010 Dec; 432(2):255-65. PubMed ID: 20868368
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Kucine N; Marubayashi S; Bhagwat N; Papalexi E; Koppikar P; Sanchez Martin M; Dong L; Tallman MS; Paietta E; Wang K; He J; Lipson D; Stephens P; Miller V; Rowe JM; Teruya-Feldstein J; Mullighan CG; Ferrando AA; Krivtsov A; Armstrong S; Leung L; Ochiana SO; Chiosis G; Levine RL; Kleppe M
Blood; 2015 Nov; 126(22):2479-83. PubMed ID: 26443624
[TBL] [Abstract][Full Text] [Related]
13. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
14. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
15. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
16. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
[TBL] [Abstract][Full Text] [Related]
17. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
18. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary.
Sutherland JM; Frost ER; Ford EA; Peters AE; Reed NL; Seldon AN; Mihalas BP; Russel DL; Dunning KR; McLaughlin EA
Mol Hum Reprod; 2018 Nov; 24(11):533-542. PubMed ID: 30247637
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.
Liu D; Huang Y; Zeng J; Chen B; Huang N; Guo N; Liu L; Xu H; Mo X; Li W
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1629-40. PubMed ID: 21861134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
